ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Sino Biopharmaceutical Ltd. ?
1
High Management Efficiency with a high ROE of 94.58%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 32.34
3
Poor long term growth as Operating profit has grown by an annual rate 3.69% of over the last 5 years
4
Positive results in Dec 24
- RAW MATERIAL COST(Y) Fallen by -2.16% (YoY)
- DEBT-EQUITY RATIO (HY) Lowest at -15.06 %
- NET PROFIT(Q) Highest at HKD 1,896.21 MM
5
With ROE of 39.17%, it has a Very Attractive valuation with a 4.48 Price to Book Value
- Over the past year, while the stock has generated a return of 102.38%, its profits have risen by 153.7% ; the PEG ratio of the company is 0.1
6
Market Beating Performance
- The stock has generated a return of 102.38% in the last 1 year, much higher than market (Hang Seng Hong Kong) returns of 26.67%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Sino Biopharmaceutical Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Sino Biopharmaceutical Ltd. for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Sino Biopharmaceutical Ltd.
100.59%
8.31
44.02%
Hang Seng Hong Kong
27.36%
1.03
25.88%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
14.51%
EBIT Growth (5y)
3.69%
EBIT to Interest (avg)
32.34
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.63
Tax Ratio
25.58%
Dividend Payout Ratio
65.98%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
134.35%
ROE (avg)
94.58%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
4.48
EV to EBIT
28.74
EV to EBITDA
22.18
EV to Capital Employed
5.11
EV to Sales
4.94
PEG Ratio
0.07
Dividend Yield
98.70%
ROCE (Latest)
17.78%
ROE (Latest)
39.17%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend
Not enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for Sino Biopharmaceutical Ltd.
Net Profit
At HKD 1,896.21 MM has Grown at 130.36%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (HKD MM)
Net Profit
Highest at HKD 1,896.21 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (HKD MM)
Debt-Equity Ratio
Lowest at -15.06 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -2.16% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at HKD 862.01 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (HKD MM)
Depreciation
At HKD 862.01 MM has Grown at 59.66%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (HKD MM)
Here's what is not working for Sino Biopharmaceutical Ltd.
EPS
Lowest at HKD 0.02
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (HKD)
Non Operating Income
Highest at HKD 0.29 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
